Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

PDL BioPharma Inc (NASDAQ:PDLI)

3.35
Delayed Data
As of 3:59pm ET
 +0.12 / +3.72%
Today’s Change
2.58
Today|||52-Week Range
5.35
-5.37%
Year-to-Date
ARIAD (ARIA) Leukemia Drug Iclusig Gets Approval in Japan
10:54am / Zacks.com - Paid Partner Content
Will PDL BioPharma (PDLI) Continue to Surge Higher?
Sep 20 / Zacks.com - Paid Partner Content
The Highest-Yielding Drug Stocks
Sep 29 / MotleyFool.com - Paid Partner Content
Forget Novavax, Buy These 4 Biotech Stocks Instead
Sep 16 / Zacks.com - Paid Partner Content
When You Should (and Shouldnt) Panic Over Earnings Results
Sep 28 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close3.23
Today’s open3.23
Day’s range3.21 - 3.37
Volume1,721,099
Average volume (3 months)1,444,792
Market cap$534.7M
Dividend yield5.97%
Data as of 3:59pm ET, 09/30/2016

Growth & Valuation

Earnings growth (last year)+9.14%
Earnings growth (this year)-74.67%
Earnings growth (next 5 years)+17.00%
Revenue growth (last year)+0.01%
P/E ratio2.4
Price/Sales0.99
Price/Book0.76

Competitors

 Today’s
change
Today’s
% change
BLCMBellicum Pharmaceuti...+0.03+0.15%
MCRBSeres Therapeutics I...-0.39-3.08%
EPZMEpizyme Inc+0.34+3.58%
ADAPAdaptimmune Therapeu...-0.14-1.95%
Data as of 3:59pm ET, 09/30/2016

Financials

Next reporting dateNovember 2, 2016
EPS forecast (this quarter)$0.08
Annual revenue (last year)$585.1M
Annual profit (last year)$332.8M
Net profit margin56.88%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
John Peter McLaughlin
Chief Financial Officer &
Vice President
Peter S. Garcia
Corporate headquarters
Incline Village, Nevada

Forecasts

Search for Jobs